International Multicentric Study ARON-1

RecruitingOBSERVATIONAL

Enrollment

1,220

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

September 30, 2027

Conditions

Metastatic Renal Cell Carcinoma (mRCC)

Interventions

DRUG

pembrolizumab plus axitinib

collect global experiences with the use of immuno-combinations in patients with metastatic RCC

Trial Locations (1)

RECRUITING

Ospedale di Macerata, UOC Oncologia, Macerata

All Listed Sponsors

lead

Hospital of Macerata

OTHER